184 related articles for article (PubMed ID: 8395306)
1. The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.
Heidbreder CA; Goldberg SR; Shippenberg TS
Brain Res; 1993 Jul; 616(1-2):335-8. PubMed ID: 8395306
[TBL] [Abstract][Full Text] [Related]
2. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.
Heidbreder CA; Schenk S; Partridge B; Shippenberg TS
Synapse; 1998 Nov; 30(3):255-62. PubMed ID: 9776129
[TBL] [Abstract][Full Text] [Related]
3. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists.
Heidbreder CA; Babovic-Vuksanovic D; Shoaib M; Shippenberg TS
J Pharmacol Exp Ther; 1995 Oct; 275(1):150-63. PubMed ID: 7562544
[TBL] [Abstract][Full Text] [Related]
4. Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine.
Vanderschuren LJ; Schoffelmeer AN; Wardeh G; De Vries TJ
Psychopharmacology (Berl); 2000 May; 150(1):35-44. PubMed ID: 10867974
[TBL] [Abstract][Full Text] [Related]
5. U-69593 prevents cocaine sensitization by normalizing basal accumbens dopamine.
Heidbreder CA; Shippenberg TS
Neuroreport; 1994 Sep; 5(14):1797-800. PubMed ID: 7827335
[TBL] [Abstract][Full Text] [Related]
6. Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission.
Collins SL; D'Addario C; Izenwasser S
Eur J Pharmacol; 2001 Aug; 426(1-2):25-34. PubMed ID: 11525767
[TBL] [Abstract][Full Text] [Related]
7. Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity.
Collins SL; Gerdes RM; D'Addario C; Izenwasser S
Behav Pharmacol; 2001 Jul; 12(4):237-45. PubMed ID: 11548109
[TBL] [Abstract][Full Text] [Related]
8. Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine.
Chefer VI; Morón JA; Hope B; Rea W; Shippenberg TS
Neuroscience; 2000; 101(3):619-27. PubMed ID: 11113311
[TBL] [Abstract][Full Text] [Related]
9. Depletion of serotonin decreases the effects of the kappa-opioid receptor agonist U-69593 on cocaine-stimulated activity.
Zakharova E; Collins SL; Aberg M; Kumar A; Fernandez JB; Izenwasser S
Eur J Pharmacol; 2008 May; 586(1-3):123-9. PubMed ID: 18395712
[TBL] [Abstract][Full Text] [Related]
10. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593.
Acri JB; Thompson AC; Shippenberg T
Synapse; 2001 Mar; 39(4):343-50. PubMed ID: 11169785
[TBL] [Abstract][Full Text] [Related]
11. U-69593, a kappa opioid receptor agonist, decreases cocaine-induced behavioral sensitization in female rats.
Puig-Ramos A; Santiago GS; Segarra AC
Behav Neurosci; 2008 Feb; 122(1):151-60. PubMed ID: 18298258
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in kappa-opioid modulation of cocaine-induced behavior and NMDA-evoked dopamine release.
Sershen H; Hashim A; Lajtha A
Brain Res; 1998 Aug; 801(1-2):67-71. PubMed ID: 9729284
[TBL] [Abstract][Full Text] [Related]
13. Sensitization to the conditioned rewarding effects of morphine and cocaine: differential effects of the kappa-opioid receptor agonist U69593.
Shippenberg TS; LeFevour A; Thompson AC
Eur J Pharmacol; 1998 Mar; 345(1):27-34. PubMed ID: 9593590
[TBL] [Abstract][Full Text] [Related]
14. The kappa-opioid receptor agonist U-69593 prevents cocaine-induced phosphorylation of DARPP-32 at Thr(34) in the rat brain.
D'Addario C; Di Benedetto M; Candeletti S; Romualdi P
Brain Res Bull; 2007 Jun; 73(1-3):34-9. PubMed ID: 17499634
[TBL] [Abstract][Full Text] [Related]
15. kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine.
Shippenberg TS; LeFevour A; Heidbreder C
J Pharmacol Exp Ther; 1996 Feb; 276(2):545-54. PubMed ID: 8632320
[TBL] [Abstract][Full Text] [Related]
16. Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593.
Schenk S; Partridge B; Shippenberg TS
Psychopharmacology (Berl); 2000 Jul; 151(1):85-90. PubMed ID: 10958121
[TBL] [Abstract][Full Text] [Related]
17. Increased locomotor response to amphetamine induced by the repeated administration of the selective kappa-opioid receptor agonist U-69593.
Fuentealba JA; Gysling K; Andrés ME
Synapse; 2007 Sep; 61(9):771-7. PubMed ID: 17568430
[TBL] [Abstract][Full Text] [Related]
18. Indirect dopamine agonists augment the locomotor activating effects of the kappa-opioid receptor agonist U-50,488 in preweanling rats.
McDougall SA; Rodarte-Freeman AL; Nazarian A
Dev Psychobiol; 1999 Apr; 34(3):183-93. PubMed ID: 10204094
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent effects of kappa-opioid receptor stimulation on cocaine-induced stereotyped behaviors and dopamine overflow in the caudate-putamen: an in vivo microdialysis study.
Cortez AM; Charntikov S; Der-Ghazarian T; Horn LR; Crawford CA; McDougall SA
Neuroscience; 2010 Aug; 169(1):203-13. PubMed ID: 20435099
[TBL] [Abstract][Full Text] [Related]
20. Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.
Perreault ML; Graham D; Scattolon S; Wang Y; Szechtman H; Foster JA
Psychopharmacology (Berl); 2007 Nov; 194(4):485-96. PubMed ID: 17619861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
